The TNBC market is advancing through immunotherapy breakthroughs and targeted treatment innovations. Leading companies including Merck, Gilead, and AstraZeneca are developing novel antibody-drug conjugates and immune checkpoint inhibitors that significantly improve clinical outcomes. Evolving biomarker identification and combination therapy approaches are enabling more effective, personalized treatment strategies for this challenging breast cancer subtype. View Full Analysis: https://shorturl.at/ruuiQ